One-stage Breast Reconstruction After Mastectomy Linked With Higher Complication Risk

Share this content:
An immediate 1-stage IBBR with use of ADMs after mastectomy may carry a higher risk for complications compared to 2-stage IBBR.
An immediate 1-stage IBBR with use of ADMs after mastectomy may carry a higher risk for complications compared to 2-stage IBBR.

An immediate 1-stage implant-based breast reconstruction (IBBR) with use of acellular dermal matrices (ADMs) after mastectomy may carry a higher risk for complications compared to 2-stage IBBR, according to a study published in The Lancet Oncology.1

Researchers conducted an open-label, randomized, controlled trial of 142 women across 8 hospitals to compare the safety between 1-stage IBBR with ADM and 2-stage IBBR.

Participants were eligible if they intended to undergo skin-sparing mastectomy as well as immediate IBBR and had a breast carcinoma or a gene mutation that was linked with breast cancer. Each was then randomized to either treatment option.

In total, 59 women, which included 91 breasts, underwent 1-stage IBBR with ADM, while 62 women, which included 92 breasts, underwent 2-stage IBBR.

Treatment with 1-stage IBBR with ADM was associated with a “significantly higher risk per breast” of surgical complications, reoperation, as well as removal of the implant, the ADM, or both, compared to treatment with 2-stage IBBR.

Twenty-six out of the 91 breasts (29%) in the group treated with 1-stage IBBR with ADM developed severe grade 3 adverse events compared to 5 of the 92 breasts (5%) in the 2-stage IBBR group. Mild to moderate adverse events had a similar frequency in the 2 groups.

RELATED: Larger Social Networks Linked With Better Breast Cancer Survival

“Understanding of selection of patients, risk factors, and surgical and post-surgical procedures needs to be improved,” the authors concluded.

Reference

  1. Dikmans REG, Negenborn VL, Bouman M, et al. Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial. Lancet Oncol. 2016 Dec 21. doi: 10.1016/S1470-2045(16)30668-4 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters